AD-HAFT included atopic dermatitis patients aged 12 years and older with moderate-to-severe hand and/or foot involvement inadequately controlled with or intolerant to topical Rx therapies who were randomized to DUPIXENT monotherapy or placebo for 16 weeks. The trial was unique as it used hand- and foot-specific measures, including IGA hand and foot, hand and foot Peak Pruritus NRS, HECSI,^a and HECSI-75.^b It was also unique because patients were screened to ensure patients with allergic contact dermatitis as a cause of their hand and foot dermatitis were excluded.^1,8,12

^aHECSI is used in clinical trials to determine the rate of severity of 6 clinical signs of hand eczema and the extent of lesions on each of 5 hand areas by use of standard scales. The total HECSI score is based on a 4-point severity scale ranging from 0 (no skin changes) to 3 (severe disease) and a 5-point scale rating the affected area(s) ranging from 0 (0% surface area affected) to 4 (76% to 100% surface area affected).

^bHECSI-75 represents an improvement of ≥75% in the Hand Eczema Severity Index.